PubRank

Len Neckers

Author PubWeight™ 154.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010 6.81
2 HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005 5.47
3 Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007 3.74
4 Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004 3.58
5 Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A 2002 3.54
6 IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003 3.37
7 Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003 3.25
8 CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J 2003 2.78
9 An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007 2.75
10 17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther 2003 2.74
11 Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst 2012 2.47
12 Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011 2.42
13 Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005 2.28
14 Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009 2.27
15 Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell 2010 2.24
16 Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002 2.17
17 UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010 2.06
18 Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007 2.06
19 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002 2.06
20 Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007 1.96
21 Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell 2011 1.94
22 Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005 1.83
23 Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010 1.82
24 Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc 2006 1.75
25 Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004 1.72
26 Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 2009 1.72
27 Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 2005 1.71
28 Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol 2005 1.67
29 Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 2009 1.67
30 Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007 1.64
31 Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer 2011 1.58
32 Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell 2008 1.57
33 Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta 2011 1.56
34 Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 2006 1.55
35 A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2003 1.54
36 Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 2002 1.54
37 Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 2003 1.50
38 Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras. Cell Cycle 2008 1.48
39 Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004 1.45
40 Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2006 1.44
41 Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006 1.40
42 Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2009 1.36
43 Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell 2012 1.35
44 The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 2003 1.35
45 The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 2013 1.33
46 Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 2009 1.32
47 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2003 1.32
48 The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity 2008 1.30
49 Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci U S A 2009 1.29
50 Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A 2008 1.28
51 A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett 2007 1.27
52 Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009 1.26
53 Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat Struct Mol Biol 2009 1.22
54 Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol Cell Biol 2006 1.18
55 Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J Biol Chem 2002 1.18
56 Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 2004 1.14
57 Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008 1.14
58 Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNK. EMBO Rep 2006 1.13
59 Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 2010 1.13
60 Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res 2006 1.13
61 Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res 2007 1.09
62 Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 2007 1.09
63 Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell 2013 1.08
64 TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget 2013 1.08
65 Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. PLoS One 2012 1.02
66 Impact of heat-shock protein 90 on cancer metastasis. Future Oncol 2009 1.00
67 The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res 2013 1.00
68 Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angew Chem Int Ed Engl 2008 0.99
69 Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res 2005 0.98
70 Post-translational modification of heat-shock protein 90: impact on chaperone function. Expert Opin Drug Discov 2007 0.97
71 Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Med Chem 2013 0.96
72 Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2011 0.96
73 Understanding of the Hsp90 molecular chaperone reaches new heights. Nat Struct Mol Biol 2010 0.94
74 Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 2007 0.93
75 Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle 2008 0.93
76 A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol 2006 0.92
77 Ras, ROS and proteotoxic stress: a delicate balance. Cancer Cell 2011 0.91
78 Visualizing the twists and turns of a molecular chaperone. Nat Struct Mol Biol 2009 0.91
79 Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle 2012 0.90
80 Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle 2010 0.90
81 Direct identification of ubiquitination sites on ubiquitin-conjugated CHIP using MALDI mass spectrometry. J Proteome Res 2005 0.89
82 Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim Biophys Acta 2006 0.89
83 ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One 2011 0.87
84 Inhibition of HSP90 with pochoximes: SAR and structure-based insights. Chembiochem 2009 0.87
85 TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget 2013 0.86
86 Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle 2011 0.86
87 Cancer: the rules of attraction. Nature 2003 0.85
88 Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin. Chem Biol 2004 0.84
89 Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chem Biol 2013 0.84
90 Detecting HSP90 phosphorylation. Methods Mol Biol 2011 0.84
91 KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res 2007 0.83
92 Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One 2013 0.82
93 Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs 2015 0.80
94 Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res 2004 0.80
95 Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex. J Biol Chem 2013 0.80
96 Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation. Cancer Sci 2008 0.79
97 Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators. J Med Chem 2013 0.79
98 Concise modular asymmetric synthesis of deguelin, tephrosin and investigation into their mode of action. Chemistry 2010 0.79
99 Just say NO: nitric oxide regulation of Hsp90. EMBO Rep 2009 0.78
100 The double edge of the HSP90-CDC37 chaperone machinery: opposing determinants of kinase stability and activity. Future Oncol 2012 0.77
101 Methoxychalcone inhibitors of androgen receptor translocation and function. Bioorg Med Chem Lett 2012 0.77
102 Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. Cell Stress Chaperones 2015 0.77
103 A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23. Mol Cell 2011 0.76
104 Quinacrine: New anti-tumor application for an old anti-malaria drug. Cell Cycle 2010 0.75
105 Targeting Hsp90 in Non-Cancerous Maladies. Curr Top Med Chem 2016 0.75
106 Epithelial-directed drug delivery: influence of formulation and delivery devices. Lung Cancer 2004 0.75